Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
NCT00419419 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
Conditions Studied
Interventions
- DRUG Topical AmphiMatrix with nitroglycerin (MQX-503)
Study Locations (12)
Other
- Lund University Hospital — Lund
- Royal National Hospital for Rheumatic Diseases — Bath
- Ninewells Hospital and Medical School — Dundee
- University of Leeds — Leeds
- Royal Free Hospital — London
- Hope Hospital — Salford
California
- Standford Medical School — Stanford
Connecticut
- University of Connecticut — Farmington
District of Columbia
- Georgetown University Medical Center — Washington D.C.
Maryland
- Johns Hopkins Bayview Medical Center — Baltimore
New York
- The Center for Rheumatology — Albany
North Carolina
- Duke University — Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419419
The ClinicalTrials.gov registry entry for NCT00419419 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediQuest Therapeutics, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Autoimmune Diseases appearing as the primary indexed condition, and to 1 intervention — of which Topical AmphiMatrix with nitroglycerin (MQX-503) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00419419 reports 12 study locations spanning 7 distinct geographic areas — top geographies include Other, California, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00419419 about?
NCT00419419 is a clinical study titled "Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon". The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
What is the current status of trial NCT00419419?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2006-12.
What conditions does trial NCT00419419 study?
This clinical trial studies the following conditions: Autoimmune Diseases, Scleroderma, Raynaud's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00419419?
The interventions under investigation include: Topical AmphiMatrix with nitroglycerin (MQX-503) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00419419?
This trial is sponsored by MediQuest Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00419419 being conducted?
This trial has 12 study locations across California, Connecticut, District of Columbia, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.